St John McGrath

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Artizan Biosciences, Inc. engages in the provision of healthcare services. It develops curative treatments for inflammatory diseases. The company was founded by Richard A. Flavell, Noah W. Palm and Marcel R. de Zoete and is headquartered in New Haven, CT.

Part of Biohaven Ltd., BioShin Ltd. is a biopharmaceutical company based in Shanghai, China. The Chinese company is advancing the Biohaven clinical portfolio in the Asia-Pacific region, excluding Japan and South Korea. BioShin is focused on discovering, developing, and commercializing novel treatments for patients with neuro-immune diseases in China and the Asia-Pacific region. The private company has a proven and established late-stage portfolio from its strategic partner, Biohaven Pharmaceuticals Inc. in the US, and is poised to quickly launch novel medicines for patients in need. The CEO of the company is Karl Lintel.